Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 5/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18513314 | 0.93 | FAAH (0.54) | CASP2FAAHCNR1DNM1LMNA | |
| SCHEMBL17123487 | 0.93 | CASP2 (0.66) | CASP2FAAHCNR1DNM1LMNA | |
| SCHEMBL27998259 | 0.91 | FAAH (0.56) | CASP2FAAHCNR1DNM1LMNA | |
| SCHEMBL17109789 | 0.91 | CASP2 (0.69) | CASP2FAAHCNR1DNM1NAAA | |
| SCHEMBL4904632 | 0.91 | CASP2 (0.62) | CASP2FAAHCNR1DNM1LMNA | |
| SCHEMBL28393843 | 0.89 | CASP2 (0.61) | CASP2FAAHCNR1DNM1NAAA | |
| SCHEMBL22923620 | 0.89 | FAAH (0.59) | CASP2FAAHCNR1DNM1NAAA | |
| SCHEMBL18513237 | 0.89 | ALDH1A1 (0.52) | CASP2FAAHCNR1DNM1LMNA | |
| SCHEMBL23471810 | 0.89 | ALDH1A1 (0.50) | CASP2FAAHCNR1DNM1LMNA | |
| SCHEMBL24810920 | 0.88 | CASP2 (0.65) | CASP2FAAHCNR1DNM1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751419-B2 | Method for synthesis of reactive conjugate clusters | IONIS PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190209694-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10751419-B2 | Method for synthesis of reactive conjugate clusters | ACOT7, COASY, LCAT | CASP2 3774/4885FAAH 1637/4885CNR1 4620/4885 |
| US-20190209694-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | CASP2 3774/4885FAAH 1637/4885CNR1 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.